BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18355919)

  • 1. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
    Vega-Ruiz A; O'Brien S; Cortes J; Kebriaei P; Thomas D; Kantarjian H; Ravandi F
    Leuk Res; 2008 Sep; 32(9):1468-71. PubMed ID: 18355919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
    Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
    Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
    Rytting ME; Wierda WG
    Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
    Thomas DA; Faderl S; Cortes J; O'Brien S; Giles FJ; Kornblau SM; Garcia-Manero G; Keating MJ; Andreeff M; Jeha S; Beran M; Verstovsek S; Pierce S; Letvak L; Salvado A; Champlin R; Talpaz M; Kantarjian H
    Blood; 2004 Jun; 103(12):4396-407. PubMed ID: 14551133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S; Rifkind J; Lipton JH
    Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
    Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
    Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
    Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
    Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
    Angstreich GR; Smith BD; Jones RJ
    Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
    Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
    Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].
    Raissi A; Bouaouad M; Drideb NA; Jennane S; Mahtat el M; Doghmi K; Mikdame M
    Ann Biol Clin (Paris); 2015; 73(2):195-8. PubMed ID: 25847743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Wassmann B; Pfeifer H; Goekbuget N; Beelen DW; Beck J; Stelljes M; Bornhäuser M; Reichle A; Perz J; Haas R; Ganser A; Schmid M; Kanz L; Lenz G; Kaufmann M; Binckebanck A; Brück P; Reutzel R; Gschaidmeier H; Schwartz S; Hoelzer D; Ottmann OG
    Blood; 2006 Sep; 108(5):1469-77. PubMed ID: 16638934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
    Jin Huh H; Won Huh J; Myong Seong C; Lee M; Soon Chung W
    Am J Hematol; 2003 Nov; 74(3):218-20. PubMed ID: 14587058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.
    Kovacsovics T; Maziarz RT
    Curr Oncol Rep; 2006 Sep; 8(5):343-51. PubMed ID: 16901395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.